Statistical Mining of Potential Drug Interaction Adverse Effects in FDA's Spontaneous Reporting System.

Many adverse drug effects (ADEs) can be attributed to drug interactions. Spontaneous reporting systems (SRS) provide a rich opportunity to detect novel post-marketed drug interaction adverse effects (DIAEs), as they include populations not well represented in clinical trials. However, their identification in SRS is nontrivial. Most existing research have addressed the statistical issues used to test or verify DIAEs, but not their identification as part of a systematic large scale database-wide mining process as discussed in this work. This paper examines the application of a highly optimized and tailored implementation of the Apriori algorithm, as well as methods addressing data quality issues, to the identification of DIAEs in FDAs SRS.

[1]  Lehana Thabane,et al.  Application of data mining techniques in pharmacovigilance. , 2003, British journal of clinical pharmacology.

[2]  G. Niklas Norén,et al.  Duplicate detection in adverse drug reaction surveillance , 2007, Data Mining and Knowledge Discovery.

[3]  Joseph M. Tonning,et al.  Perspectives on the Use of Data Mining in Pharmacovigilance , 2005, Drug safety.

[4]  William DuMouchel,et al.  Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System , 1999 .

[5]  M. Hauben,et al.  Data mining for signals in spontaneous reporting databases: proceed with caution , 2007, Pharmacoepidemiology and drug safety.

[6]  Cédric Bousquet,et al.  Mining for Adverse Drug Events with Formal Concept Analysis , 2009, MIE.

[7]  Tomasz Imielinski,et al.  Mining association rules between sets of items in large databases , 1993, SIGMOD Conference.

[8]  A. Borobia,et al.  A Pharmacovigilance Program From Laboratory Signals for the Detection and Reporting of Serious Adverse Drug Reactions in Hospitalized Patients , 2010, Clinical pharmacology and therapeutics.

[9]  Carol Friedman,et al.  Mining multi-item drug adverse effect associations in spontaneous reporting systems , 2010, BMC Bioinformatics.

[10]  W. DuMouchel,et al.  Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post‐marketing setting , 2003, Pharmacoepidemiology and drug safety.

[11]  W. DuMouchel,et al.  Novel Statistical Tools for Monitoring the Safety of Marketed Drugs , 2007, Clinical pharmacology and therapeutics.

[12]  William DuMouchel,et al.  Empirical bayes screening for multi-item associations , 2001, KDD '01.

[13]  R. Meyboom,et al.  Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. , 1999, British journal of clinical pharmacology.

[14]  A. Bate,et al.  A Bayesian neural network method for adverse drug reaction signal generation , 1998, European Journal of Clinical Pharmacology.

[15]  R. O’Neill,et al.  Use of Screening Algorithms and Computer Systems to Efficiently Signal Higher-Than-Expected Combinations of Drugs and Events in the US FDA’s Spontaneous Reports Database , 2002, Drug safety.

[16]  George Hripcsak,et al.  Automated encoding of clinical documents based on natural language processing. , 2004, Journal of the American Medical Informatics Association : JAMIA.

[17]  Bharat T Thakrar,et al.  Detecting signals of drug-drug interactions in a spontaneous reports database. , 2007, British journal of clinical pharmacology.

[18]  A. Bate,et al.  Quantitative signal detection using spontaneous ADR reporting , 2009, Pharmacoepidemiology and drug safety.